Clinical demographic features and cardiopulmonary measurements stratified by exercise echocardiogram (EE) result.
| Features and Measurements | Positive EE, n = 43 (51%) | Negative EE, n = 42 (49%) | p |
|---|---|---|---|
| Age, yrs ± SD | 54.7 ± 11.8 | 51.3 ± 13 | 0.27 |
| Disease duration, yrs ± SD | 7.9 ± 7.1 | 6.3 ± 6 | 0.46 |
| Race, n (%) | 0.68 | ||
| White | 22 (51) | 24 (57) | |
| African American | 19 (44) | 15 (36) | |
| Antibodies, n % | 0.44 | ||
| Anticentromere | 12 (28) | 14 (33) | |
| Scl-70 | 5 (12) | 9 (21) | |
| Antinucleolar | 11 (26) | 8 (19) | |
| SSc type, limited, % | 26 (60) | 30 (71) | 0.28 |
| FVC, % ± SD | 84.5 ± 20 | 85.7 ± 22.3 | 0.88 |
| DLCO, % ± SD | 62.6 ± 22.3 | 64.7 ± 20 | 0.42 |
| FVC(%)/DLCO(%) ± SD | 1.5 ± 0.4 | 1.4 ± 0.5 | 0.83 |
| Baseline 6-MWT, m ± SD | 434.6 ± 103.7 | 450.6 ± 98.6 | 0.74 |
| Baseline RVSP, mmHg ± SD | 33.2 ± 7.5 | 31.5 ± 5.7 | 0.39 |
| ΔRVSP, mm Hg ± SD | 21.7 ± 7.9 | 10.7 ± 5.4 | < 0.01 |
| RHC mPAP*, mmHg ± SD | 20.0 ± 4.9 | 20.4 ± 5.9 | 0.67 |
| RHC PAWP*, mmHg ± SD | 10.5 ± 5.4 | 12.3 ± 3.7 | 0.19 |
| Time to followup, yrs ± SD | 5 ± 2.4 | 4.7 ± 2.4 | 0.56 |
| Developed PH, n (%) | 10 (23) | 3 (7) | 0.04 |
↵* n = 18 for negative EE group. SSc: systemic sclerosis; limited: limited cutaneous SSc; FVC: forced vital capacity; 6-MWT: 6-minute walk test; RVSP: right ventricular systolic pressure; PH: pulmonary hypertension: RHC: right heart catheterization; mPAP: mean pulmonary arterial pressure; PAWP: pulmonary artery wedge pressure.